enGene Therapeutics Inc.
ENGN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001980845
In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 60 institutions reported holding it in 13F filings for Q2 2026, worth $86.5M in total; no superinvestor holds it.
Other share classesENGNW
Q2 2026 vs. Q1 2026
How the institutions holding enGene Therapeutics Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Of which not filed for Q2 2026 | Q2 2026 | Change |
|---|---|---|---|---|
| Holders | 62 | 1 | 60 | −1 |
| Shares | 56.2M | 90.0K | 50.0M | −6.14M (−10.9%) |
| Value | $383.0M | $612.9K | $86.5M | −$295.8M (−77.4%) |
1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (21)
Institutions that held enGene Therapeutics Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BML Capital Management, LLC | 6,669,908 | $11.5M | 6.59% |
| Ameriprise Financial Inc | 2,675,876 | $4.63M | 0.00% |
| Acorn Capital Advisors, LLC | 1,271,257 | $2.20M | 0.60% |
| Peapod Lane Capital LLC | 1,102,149 | $1.91M | 1.29% |
| Seven Fleet Capital Management LP | 411,065 | $711.1K | 0.12% |
| Rangeley Capital, LLC | 305,102 | $527.8K | 0.52% |
| Qube Research & Technologies Ltd | 200,187 | $346.3K | 0.00% |
| Marquette Asset Management, LLC | 150,546 | $260.4K | 0.03% |
| Persistent Asset Partners Ltd | 114,493 | $198.1K | 0.06% |
| Jain Global LLC | 43,231 | $74.8K | 0.00% |
| Scientech Research LLC | 40,710 | $70.4K | 0.06% |
| Verdad Advisers, LP | 39,300 | $68.0K | 0.07% |
| Gsa Capital Partners LLP | 37,346 | $65.0K | 0.00% |
| Engineers Gate Manager LP | 27,286 | $47.2K | 0.00% |
| Susquehanna International Group, LLP | 24,470 | $42.3K | 0.00% |
| Sectoral Asset Management Inc | 21,700 | $37.5K | 0.03% |
| Fountainhead AM, LLC | 15,000 | $25.9K | 0.02% |
| Virtu Financial LLC | 13,986 | $24.0K | 0.00% |
| Wolverine Asset Management LLC | 2,964 | $5.13K | 0.00% |
| Simplex Trading, LLC | 399 | $690 | 0.00% |
| Farther Finance Advisors, LLC | 100 | $173 | 0.00% |
Sold out (22)
Institutions that held enGene Therapeutics Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| VR Adviser, LLC | 4,771,414 | $32.5M |
| Blue Owl Capital Holdings LP | 4,416,353 | $30.1M |
| Deep Track Capital, LP | 4,377,572 | $29.8M |
| Braidwell LP | 2,456,870 | $16.7M |
| MPM Oncology Impact Management LP | 1,845,373 | $12.6M |
| Franklin Resources Inc | 1,314,993 | $8.96M |
| Polar Capital Holdings Plc | 1,224,071 | $8.34M |
| Marshall Wace, LLP | 343,928 | $2.34M |
| Monashee Investment Management LLC | 320,000 | $2.18M |
| Birchview Capital, LP | 250,000 | $1.70M |
| FMR LLC | 232,200 | $1.58M |
| Trexquant Investment LP | 104,697 | $713.0K |
| Geode Capital Management, LLC | 38,802 | $264.2K |
| American Century Companies Inc | 32,861 | $223.8K |
| Northern Trust Corp | 30,085 | $204.9K |
| ExodusPoint Capital Management, LP | 26,613 | $181.2K |
| Pale Fire Capital SE | 24,004 | $163.5K |
| Jump Financial, LLC | 21,633 | $147.3K |
| Mirabella Financial Services LLP | 13,962 | $95.1K |
| JPMorgan Chase & Co | 1,977 | $12.2K |
| Caitong International Asset Management Co., Ltd | 163 | $1.11K |
| Citigroup Inc | 99 | $674 |
Not filed for Q2 2026 yet (1)
Institutions that held enGene Therapeutics Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Deeter Investments LLP | 90,000 | $612.9K |